Different signaling pathways mediate stimulated secretions of endogenous ouabain and aldosterone from bovine adrenocortical cells.
Angiotensin II stimulates secretion of corticosteroids and an ouabain-like compound from adrenocortical cells. The angiotensin AT1 and AT2 receptor subtypes have been linked with stimulated secretion of aldosterone and endogenous ouabain, respectively, but the second messenger mechanisms involved in the latter secretion are not known. Accordingly, we investigated the effects of several pharmacological agents that affect signaling pathways on the basal and stimulated secretions of aldosterone and endogenous ouabain from primary cell cultures of bovine adrenocortical cells. The AT2 receptor antagonist, PD 123319, blocked the effects of angiotensin II on secretion of endogenous ouabain but not aldosterone. Treatment of the cells with either dibutyryl cAMP, a membrane permeant analog, or the phorbol ester tetradecanoyl phorbol acetate stimulated aldosterone secretion but had no effect on the secretion of endogenous ouabain. On the other hand, the membrane permeant analog, 8BcGMP, maximally activated secretion of endogenous ouabain whereas incubation of cells with sodium orthovanadate blocked angiotensin II stimulated secretion of endogenous ouabain. Neither 8BcGMP nor sodium orthovanadate affected the basal or stimulated components of aldosterone secretion. These results show that the secretions of aldosterone and endogenous ouabain from bovine adrenocortical cells are mediated by different intracellular signaling mechanisms and provide evidence that the adrenal secretions of these steroids are regulated differently.
Shah
J R
JR
Department of Physiology, University of Maryland at Baltimore, 21201, USA.
Laredo
J
J
Hamilton
B P
BP
Hamlyn
J M
JM
D000302:Adrenal Cortex / Q000187:drug effects / Q000378:metabolism*; D000324:Adrenocorticotropic Hormone / Q000494:pharmacology; D000450:Aldosterone / Q000378:metabolism*; D000804:Angiotensin II / Q000494:pharmacology*; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D001685:Biological Factors / Q000378:metabolism*; D003994:Bucladesine / Q000494:pharmacology; D002298:Cardenolides; D002417:Cattle; D002478:Cells, Cultured; D004077:Digoxin; D004791:Enzyme Inhibitors / Q000378:metabolism; D007093:Imidazoles / Q000494:pharmacology; D010042:Ouabain / Q000378:metabolism*; D011725:Pyridines / Q000494:pharmacology; D044139:Receptor, Angiotensin, Type 2; D012503:Saponins; D015398:Signal Transduction; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D015384:Zona Glomerulosa / Q000187:drug effects / Q000378:metabolism
D057911:Angiotensin Receptor Antagonists; D001685:Biological Factors; D002298:Cardenolides; D004791:Enzyme Inhibitors; D007093:Imidazoles; D011725:Pyridines; D044139:Receptor, Angiotensin, Type 2; D012503:Saponins; C034504:digoxin-like factors; D000804:Angiotensin II; C073402:PD 123319; D000450:Aldosterone; D010042:Ouabain; D003994:Bucladesine; D004077:Digoxin; D000324:Adrenocorticotropic Hormone; D013755:Tetradecanoylphorbol Acetate